Quality | 2009.11.04
ProChon Biotech Selects Lonza to Locally Manufacture Critical Component of BioCart™ Cartilage Regeneration System
WOBURN, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--ProChon Biotech, Ltd., an innovator of tissue regenerative technologies to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced that it selected Lonza’s Hopkinton, Mass. facility to manufacture its proprietary fibroblast growth factor (FGF2v) variant in the United States. FGF2v is a key regulator of cellular processes involved in blood vessel formation, wound healing and
For more information, please visit
http://www.businesswire.com/news/home/20091104005955/en
